



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Preface

A New Era in the Treatment of Allergic Disorders



Lanny J. Rosenwasser, MD
Editor

Biologics have revolutionized medical therapy in the past 2 decades. Allergic Diseases have benefited from this revolution as a variety of biologics have impacted all categories of allergic diseases. Anticytokines directed at type 2 immunity has helped in the treatment of all allergic conditions covered in this issue ranging from Allergic Rhinitis to Asthma to Atopic Dermatitis to Food Allergy and others. Obviously, the ravages of COVID-19 on processes involved in biologic treatment are a consideration, but current thinking suggests such therapies should not be affected by the pandemic.¹

Lanny J. Rosenwasser, MD
Department of Medicine
UMKC School of Medicine
Kansas City, MO 64106, USA

E-mail address:
rosenwasser334@gmail.com

REFERENCE

1. Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma, and biological therapies: what we need to know. *World Allergy Organ J* 2020;13:100126.